| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Aloeresin D targets beta-secretase 1 (BACE1), an enzyme involved in the production of amyloid-beta peptides in the brain. By inhibiting BACE1, it may have potential applications in the study of Alzheimer's disease. It inhibits BACE1 activity with an IC50 of 39 microM.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Aloeresin D is an inhibitor of BACE1 activity with an IC50 of 39 microM. Its activity is assessed in biochemical assays using purified BACE1 enzyme and a fluorogenic substrate. It is a natural compound isolated from Aloe vera and is used as a reference standard.
|
| ln Vivo |
In vivo activity of Aloeresin D has not been extensively characterized. As a BACE1 inhibitor, it has potential for research into Alzheimer's disease. However, as a natural product, its bioavailability and in vivo efficacy would need to be evaluated in appropriate animal models.
|
| Enzyme Assay |
In vitro enzyme assays for Aloeresin D involve measuring its inhibition of BACE1 activity. The assay typically uses purified BACE1 enzyme and a fluorogenic peptide substrate. The compound is incubated with the enzyme and substrate, and the fluorescence is measured to determine the rate of substrate cleavage. The IC50 value of 39 microM is calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for Aloeresin D are limited. As a BACE1 inhibitor, its effects could be studied in cell lines that express BACE1 and produce amyloid-beta peptides. Cells would be treated with the compound, and the levels of amyloid-beta in the culture medium would be measured by ELISA.
|
| Animal Protocol |
In vivo animal studies for Aloeresin D are limited. For studying its potential in Alzheimer's disease, transgenic mouse models that produce amyloid-beta plaques could be used. Animals would be treated with the compound, and its effects on plaque formation and cognitive function would be assessed.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Aloeresin D are characteristic of a glycoside. It has a molecular weight of 556.56 and a molecular formula of C29H32O11. It is soluble in DMSO and is typically stored at -20degC. Its high molecular weight and glycosidic structure may limit oral bioavailability.
|
| Toxicity/Toxicokinetics |
The toxicological data for Aloeresin D are limited. As a natural product from Aloe vera, it is generally considered to have a low toxicity profile. However, it is intended for research and analytical applications only and is not for human therapeutic use. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
According to reports, aloin D is found in Aloe ferox, Aloe africana, and other organisms with relevant data.
Aloeresin D is a chromone glycoside from Aloe vera that inhibits BACE1 activity. It is used as a standard for analytical applications. It is a flavonoid with potential applications in Alzheimer's disease research. It is available in high purity. |
| Molecular Formula |
C29H32O11
|
|---|---|
| Molecular Weight |
556.5578
|
| Exact Mass |
556.194
|
| CAS # |
105317-67-7
|
| PubChem CID |
14211225
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
796.8±60.0 °C at 760 mmHg
|
| Flash Point |
261.7±26.4 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.659
|
| LogP |
2.98
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
40
|
| Complexity |
942
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC1=CC(=C(C2=C1C(=O)C=C(O2)C[C@@H](C)O)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)OC(=O)/C=C/C4=CC=C(C=C4)O)OC
|
| InChi Key |
OUGNWRCWQLUXHX-ACWXGELRSA-N
|
| InChi Code |
InChI=1S/C29H32O11/c1-14-10-20(37-3)24(27-23(14)19(33)12-18(38-27)11-15(2)31)28-29(26(36)25(35)21(13-30)39-28)40-22(34)9-6-16-4-7-17(32)8-5-16/h4-10,12,15,21,25-26,28-32,35-36H,11,13H2,1-3H3/b9-6+/t15-,21-,25-,26+,28+,29-/m1/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[2-[(2R)-2-hydroxypropyl]-7-methoxy-5-methyl-4-oxochromen-8-yl]oxan-3-yl] (E)-3-(4-hydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~449.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7968 mL | 8.9838 mL | 17.9675 mL | |
| 5 mM | 0.3594 mL | 1.7968 mL | 3.5935 mL | |
| 10 mM | 0.1797 mL | 0.8984 mL | 1.7968 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
